Medpace and Ardent Health Financial Review Compares Medical Companies

Analysts see more upside potential in Ardent Health stock compared to Medpace.

Published on Feb. 12, 2026

Got story updates? Submit your updates here. ›

Medpace (NASDAQ:MEDP) and Ardent Health (NYSE:ARDT) are both medical companies, but analysts believe Ardent Health is the more favorable stock based on its stronger consensus rating and higher potential upside. The article compares the two companies across factors like dividends, profitability, risk, analyst recommendations, valuation, earnings, and institutional ownership.

Why it matters

This analysis provides investors with a side-by-side comparison of two prominent medical companies, highlighting their relative strengths and weaknesses. Understanding the differences between Medpace and Ardent Health can help investors make more informed decisions about where to allocate their capital in the healthcare sector.

The details

Medpace has higher earnings but lower revenue than Ardent Health, and Ardent Health is trading at a lower price-to-earnings ratio, indicating it is currently more affordable. Medpace also has higher institutional ownership and more volatile stock price compared to Ardent Health. Analysts' consensus price targets suggest Ardent Health has 55.97% potential upside, compared to 12.60% for Medpace.

  • The article was published on February 12, 2026.

The players

Medpace

A medical company that provides outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries.

Ardent Health

A medical company that owns and operates a network of hospitals and clinics providing a range of healthcare services in the United States.

Got photos? Submit your photos here. ›

The takeaway

This analysis highlights the differences between two prominent medical companies, Medpace and Ardent Health, and suggests that Ardent Health may be the more favorable investment option based on its stronger consensus rating, higher potential upside, and lower valuation compared to Medpace.